QurieGen develops QuRIE-seq, a patented single-cell technology platform that simultaneously quantifies mRNA and hundreds of membrane proteins, intracellular proteins, and phosphoproteins. The platform is positioned to enhance drug discovery and development by decoding cellular responses. The company is led by CEO Kinga Matula. QurieGen operates at the interface between the Netherlands and Poland, leveraging scientific resources in the Netherlands and the Polish technology ecosystem. It recently raised €2.2M to support growth. The firm intends to use the proceeds to expand operations and R&D efforts.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025